secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001437749-25-013987
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia announces first patient enrolled in Phase 3 CardiAMP HF II heart failure trial
--------------------------------------------------------------------------------

- First patient enrolled in Phase 3 randomized, double-blind, placebo-controlled CardiAMP HF II trial at BayCare Morton Plant Hospital in Clearwater, Florida.
- 250-patient multicenter study targeting ischemic HFrEF patients with elevated NTproBNP; composite primary endpoint includes death, nonfatal MACE, and quality of life.
- Company preparing regulatory submissions in Japan and the USA based on prior CardiAMP HF, TAC-HFT, and TABMMI trial data.
- Advances include cell population analysis at screening to define treatment doses and use of FDA-approved Morph DNA steerable catheter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925013987/0001437749-25-013987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925013987/bcda20250501_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-013987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer